Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma
The Oncologist · 03.10.2024 · 29 (10) · 887-893
DOI: 10.1093/oncolo/oyae180 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.07.2024. Verfasst von Andres F Correa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, United States. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Circulating Tumor DNA, Kidney Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years. Accurate assessment of prognosis in high-risk patients would aid in improving outcomes. Here we evaluate the use of circulating tumor DNA (ctDNA) in RCC using banked samples and clinical data from a single institution.
Methods
The cohort consisted of 45 RCC patients (≥pT1b) who underwent complete resection. The presence of ctDNA in plasma was determined using a personalized, tumor-informed ctDNA assay (Signatera RUO, Natera, Inc.). Relationships with outcomes and other relevant clinical variables were assessed. The median follow-up was 62 months.
Results
Plasma ctDNA was detected in 18 out of 36 patients (50%) pre-operatively and was associated with increased tumor size (mean 9.3 cm vs. 7.0 cm, P < .05) and high Fuhrman grade (60% grades III-IV vs 27% grade II, P = .07). The presence of ctDNA, either pre-operatively or at any time post-operatively, was associated with inferior relapse-free survival (HR = 2.70, P = .046; HR = 3.23, P = .003, respectively). Among patients who were ctDNA positive at any time point, the sensitivity of relapse prediction was 84% with a PPV of 90%. Of note, ctDNA positivity at a post-surgical time point revealed a PPV of 100% and NPV of 64%. The lack of ctDNA detection at both time points yielded an NPV of 80%.
Conclusions
Detection of plasma ctDNA using a personalized assay is prognostic of recurrence in patients with resected RCC. Herein, we describe a successful approach for its application and identify potential limitations to be addressed in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, United States.
- Natera, Inc., Novato, CA, United States.
- Biosample Repository Facility, Fox Chase Cancer Center, Philadelphia, PA, United States.
- WuXi Advanced Therapies, Cheltenham, PA, United States.
- Nuclear Dynamics and Cancer, Fox Chase Cancer Center, Philadelphia, PA, United States.
- Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, United States.
ORCID-Profile: Philip H Abbosh
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Correa, A. F., Kalashnikova, E., Wu, H. T., Winters, R. M., Balcioglu, M., Sudhaman, S., Connolly, D. C., Gong, Y., Uzzo, R. G., Sethi, H., ElNaggar, A. C., Aleshin, A., Liu, M. C., & Abbosh, P. H. (2024). Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma. The Oncologist, 29(10), 887-893. https://doi.org/10.1093/oncolo/oyae180
Vancouver
Correa AF, Kalashnikova E, Wu HT, Winters RM, Balcioglu M, Sudhaman S, et al. Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma. The Oncologist. 2024;29(10):887-893. doi:10.1093/oncolo/oyae180
BibTeX
@article{Correa2024,
author = {Correa, Andres F and Kalashnikova, Ekaterina and Wu, Hsin-Ta and Winters, Ryan M and Balcioglu, Mustafa and Sudhaman, Sumedha and Connolly, Denise C and Gong, Yulan and Uzzo, Robert G and Sethi, Himanshu and ElNaggar, Adam C and Aleshin, Alexey and Liu, Minetta C and Abbosh, Philip H},
title = {Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {10},
pages = {887--893},
doi = {10.1093/oncolo/oyae180}
}
EUVIMED